Your search for comorbidities returned 23 results

Stroke/systemic embolism rates were comparable between patients with atrial fibrillation with or without heart failure.

The hazard ratio for cancer associated with heart failure was 2.16 and was 1.71, after adjustments.

The American College of Cardiology released a decision pathway addressing 10 pivotal issues in heart failure with reduced ejection fraction.

Technical success was achieved in 46 patients, according to Mitral Valve Academic Research Consortium criteria.

Implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators manufactured by St. Jude Medical may have batteries that will prematurely deplete.

Patients with heart failure with reduced ejection fraction who received any guideline-directed medical therapy were less likely to die within 1 year of implantable cardioverter-defibrillator placement.

Out 952 patients, 20 experienced sudden cardiac death/malignant ventricular arrhythmias within the first 6 months of the study enrollment.

Structural heart disease variables associated with death included left ventricular ejection fraction ≤45% and right ventricular systolic dysfunction.

Long-chain acylcarnitine metabolites (factors 5 and 7) were associated with an increased risk of all-cause mortality or hospitalization.

Researchers analyzed the relationship between chronotropic incompetence and exercise capacity in patients with chronic heart failure.